The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder

J Child Adolesc Psychopharmacol. 2017 Jun;27(5):429-432. doi: 10.1089/cap.2016.0111. Epub 2017 Feb 16.

Abstract

Objective: To assess the Empathizing Quotient (EQ) of patients diagnosed with attention-deficit/hyperactivity disorder (ADHD) only or comorbid with oppositional defiant disorder (ODD) and compare the two groups' responses to methylphenidate (MPH) treatment.

Methods: Fifty-two children (8-18 years) diagnosed with ADHD, 26 of whom were also diagnosed with comorbid ODD (ADHD/ODD), were treated with MPH for 12 weeks. The level of EQ was assessed with the Children's version of the Empathizing Quotient (EQ-C) and the severity of ADHD symptoms with the ADHD Rating Scale (ADHD-RS). Assessments were done at baseline and at end point.

Results: A significant increase in EQ scores was obtained in both groups following MPH treatment (p = 0.003 for ADHD/ODD; p = 0.002 for ADHD). Significant correlation was found in the ADHD group between the changes in ADHD-RS and those in EQ, following MPH treatment (p = 0.015), but not in the ADHD/ODD group (p = 0.48).

Conclusions: A correlation exists between MPH-related improvement in ADHD symptoms and between more empathy in children with ADHD not comorbid with ODD.

Keywords: Empathizing Quotient (EQ); attention-deficit/hyperactivity disorder (ADHD); children and adolescents; methylphenidate (MPH); oppositional defiant disorder (ODD).

MeSH terms

  • Adolescent
  • Attention Deficit Disorder with Hyperactivity / complications
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit and Disruptive Behavior Disorders / complications
  • Attention Deficit and Disruptive Behavior Disorders / drug therapy*
  • Central Nervous System Stimulants / therapeutic use
  • Child
  • Empathy / drug effects*
  • Humans
  • Methylphenidate / therapeutic use*
  • Psychiatric Status Rating Scales
  • Severity of Illness Index

Substances

  • Central Nervous System Stimulants
  • Methylphenidate